Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Aug
20
Today In Oncology
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events
Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital
Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?
Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo